Translate
Neurocrine Biosciences Inc
About
Neurocrine Biosciences Inc (NASDAQ:NBIX) — investor relations, events, news, and company updates on 6ix.
Latest News
Yesterday
Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale
Apr 22 2026
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
Apr 14 2026
Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR
Apr 14 2026
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results
Apr 12 2026
Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia
Recent Videos
Gilead Makes Its Third Acquisition in 6 Weeks • Neurocrine Pays $2.9B for Prader-Willi Drug
Apr 08, 2026
Gilead strikes again, penning $5bn deal to buy Tubulis #lifesciences #pharmanews #news
Apr 07, 2026
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9B | Trialt–Viedoc Deal
Apr 07, 2026
Neurocrine Acquires Soleno for $2.9B, Expanding into Rare Metabolic Diseases #digitalfincorp
Apr 07, 2026
Financials
Revenue
$2.86 B
Market Cap
$13.21 B
P/E Ratio
28.18
EPS
4.67
